Artificial intelligence (AI) is playing an increasingly relevant and important role in our lives.  Be it through your personal devices, streaming platforms or the production of vaccines, our symbiotic relationship with AI is unquestionable. This rapid rise in the use of AI raises challenging questions for patent law:

Continue Reading Thaler Shut Down: High Court of Australia confirms AI incapable of being an “inventor”

In November 2021, we reported on a consultation by the UK Intellectual Property Office (“UKIPO”) on potential amendments to existing intellectual property law in light of AI created works and inventions. The consultation sought responses on three key issues:

  • copyright protection for computer-generated works without a human author;


Continue Reading I, Creator: UK Intellectual Property Office publishes its response to consultation on AI and intellectual property law

Background: Initial Call for Views and UK Government Response

Earlier this year DLA Piper reported on the UK government’s response to its consultation on AI and potential amendments to existing intellectual property law. The initial call for views sought to gain insight into how individuals and organisations believe that AI
Continue Reading UK consultation on treatment of AI in copyright and patents legislation

By Michal Kasprowicz and Sangeetha Punniyamoorthy

Due to the coronavirus disease 2019 (COVID-19) pandemic there have been recent amendments to Canada’s Patent Act that will authorize the use of certain patented inventions necessary to respond in a public health emergency. These measures will authorize the manufacturing and distribution of patented
Continue Reading COVID-19’s Impact on Canadian patent owners

Trial and error – with the vast majority of trials ending in error – has long been the default method of drug discovery. Of the USD2.6 billion spent each year on drug discovery by the world’s largest pharmaceutical companies, at least nine-tenths will go toward funding drug research that will
Continue Reading The error of trials: Legal considerations when deploying AI in drug development